Genocea Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 74
- Market Cap
- -
- Website
- http://www.genocea.com
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
- Conditions
- MelanomaNon-small Cell Lung CancerRenal Cell CarcinomaSmall-cell Lung CancerCutaneous Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaAnal Squamous Cell CarcinomaMerkel Cell Carcinoma
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04596033
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
- Conditions
- Non-small Cell Lung CancerUrothelial CarcinomaSquamous Cell Carcinoma of the Head and NeckCutaneous MelanomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03633110
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸John Wayne Cancer Institute - Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸University of Colorado, Anschutz Cancer Pavilion, Aurora, Colorado, United States
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
- Conditions
- Genital HerpesHSV-2 Infection
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03146403
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Optimus Medical Group, San Francisco, California, United States
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
- Conditions
- Genital Herpes Simplex Type 2
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02910284
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- Biological: Matrix-M2Drug: PlaceboBiological: GEN-003
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT02515175
- Locations
- 🇺🇸
University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
- Prev
- 1
- 2
- Next